Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 26,454 shares at $794.57 ($21.1M) on 2023-11-14, disclosed to the SEC on 2023-11-15.
Scheduled sale ($21.1M) by EVP Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $795.69 | 13,508 | $10.7M | 51.0% |
| 2 | $794.57 | 752 | $598K | 2.8% |
| 3 | $794.57 | 752 | $598K | 2.8% |
| 4 | $795.38 | 347 | $276K | 1.3% |
| 5 | $795.38 | 347 | $276K | 1.3% |
| 6 | $797.79 | 204 |
| $163K |
| 0.8% |
| 7 | $797.79 | 204 | $163K | 0.8% |
| 8 | $798.63 | 1,614 | $1.3M | 6.1% |
| 9 | $798.63 | 1,614 | $1.3M | 6.1% |
| 10 | $799.48 | 1,601 | $1.3M | 6.1% |
| 11 | $799.48 | 1,601 | $1.3M | 6.1% |
| 12 | $800.55 | 382 | $306K | 1.4% |
| 13 | $800.55 | 382 | $306K | 1.4% |
| 14 | $801.56 | 877 | $703K | 3.3% |
| 15 | $801.56 | 877 | $703K | 3.3% |
| 16 | $802.63 | 347 | $279K | 1.3% |
| 17 | $802.63 | 347 | $279K | 1.3% |
| 18 | $803.38 | 330 | $265K | 1.3% |
| 19 | $803.38 | 330 | $265K | 1.3% |
| 20 | $804.89 | 19 | $15K | 0.1% |
| 21 | $805.00 | 19 | $15K | 0.1% |
| Total | $797.38 avg | 26,454 | $21.1M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2022-11-16 | $5.2M | — | Filing → |